Skip to main content

Table 2 Lipids and other biomarkers at baseline and at 3 and 6 months after the ezetimibe therapy

From: Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia

Parameters Pre Post 3M Post 6M
Body mass index (kg/m2) 27.9 ± 3.5 27.5 ± 3.4*** 27.6 ± 3.4*
Waist circumference (cm) 93.6 ± 8.5 91.8 ± 7.8*** 91.5 ± 7.9***
Systolic blood pressure (mmHg) 128.7 ± 14.8 127.2 ± 13.9 127.0 ± 13.0
Diastolic blood pressure (mmHg) 76.0 ± 9.4 75.6 ± 9.4 74.4 ± 10.3
Total cholesterol (mg/dl) 236.2 ± 34.7 208.9 ± 31.9*** 207.0 ± 34.5***
LDL-cholesterol (mg/dl) 147.9 ± 29.5 125.5 ± 25.9*** 126.5 ± 30.5***
HDL-cholesterol (mg/dl) 51.7 ± 10.7 52.7 ± 10.3 54.5 ± 9.8***
Non HDL-cholesterol (mg/dl) 184.5 ± 30.7 156.2 ± 29.1*** 151.9 ± 32.6***
Triglycerides+ (mg/dl) 162.4 145.5* 134.3***
RLP-cholesterol+ (mg/dl) 6.6 5.2*** 4.7***
Free fatty acid+ (mEq/l) 437.0 454.8 483.0
Plasma glucose (mg/dl) 106.4 ± 28.8 107.3 ± 24.5 103.3 ± 24.1
Insulin+ (μU/ml) 11.9 11.1 10.0*
HOMA index+ 3.1 2.8 2.6
hsCRP+ (mg/dl) 765.1 820.6 871.3
Aldosterone (pg/dl)+ 90.9 97.5 96.5
HGF (ng/ml) 0.32 ± 0.06 0.31 ± 0.04 0.30 ± 0.03*
Adiponectine (μg/ ml)+ 2.58 2.64 2.53
EPA/AA+ 0.31 0.31 0.31
  1. *: p < 0.05, ***: p < 0.001.
  2. Data are means (SD), geometric mean and range. *: These variables are shown in the original scale after analysis using log (natural)-transformed values.
  3. Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to arachidonic acid.